Q2 2025 EPS Estimates for Exelixis, Inc. Lowered by Zacks Research (NASDAQ:EXEL)

Exelixis, Inc. (NASDAQ:EXEL) – Investment analysts at Zacks Research lowered their Q2 2025 earnings estimates for shares of Exelixis in a research note issued on Monday, September 16th. Zacks Research analyst E. Bagri now forecasts that the biotechnology company will earn $0.34 per share for the quarter, down from their previous estimate of $0.37. The consensus estimate for Exelixis’ current full-year earnings is $1.54 per share. Zacks Research also issued estimates for Exelixis’ Q3 2025 earnings at $0.34 EPS and Q1 2026 earnings at $0.39 EPS.

Several other equities research analysts also recently weighed in on EXEL. Royal Bank of Canada restated an “outperform” rating and issued a $27.00 target price on shares of Exelixis in a research note on Wednesday, August 7th. Truist Financial restated a “buy” rating and issued a $33.00 target price (up from $32.00) on shares of Exelixis in a research note on Thursday, August 8th. Oppenheimer restated an “outperform” rating and issued a $29.00 target price on shares of Exelixis in a research note on Tuesday, July 30th. HC Wainwright restated a “buy” rating and issued a $29.00 target price on shares of Exelixis in a research note on Wednesday. Finally, StockNews.com upgraded shares of Exelixis from a “buy” rating to a “strong-buy” rating in a research note on Saturday, July 13th. Four research analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Exelixis has an average rating of “Moderate Buy” and an average price target of $27.50.

Exelixis Stock Down 2.8 %

Shares of EXEL opened at $26.82 on Thursday. The company has a market cap of $8.13 billion, a price-to-earnings ratio of 41.91, a price-to-earnings-growth ratio of 0.58 and a beta of 0.54. Exelixis has a twelve month low of $18.64 and a twelve month high of $27.83. The company has a 50 day moving average of $24.94 and a two-hundred day moving average of $23.26.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.31 by $0.44. Exelixis had a net margin of 17.38% and a return on equity of 15.54%. The firm had revenue of $637.18 million during the quarter, compared to analysts’ expectations of $468.21 million.

Insider Buying and Selling

In related news, EVP Dana Aftab sold 95,000 shares of the firm’s stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $25.00, for a total transaction of $2,375,000.00. Following the completion of the transaction, the executive vice president now owns 520,990 shares of the company’s stock, valued at $13,024,750. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other Exelixis news, CFO Christopher J. Senner sold 125,000 shares of Exelixis stock in a transaction on Friday, August 9th. The shares were sold at an average price of $27.19, for a total value of $3,398,750.00. Following the completion of the transaction, the chief financial officer now owns 721,680 shares of the company’s stock, valued at $19,622,479.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Dana Aftab sold 95,000 shares of Exelixis stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $25.00, for a total transaction of $2,375,000.00. Following the completion of the transaction, the executive vice president now directly owns 520,990 shares of the company’s stock, valued at approximately $13,024,750. The disclosure for this sale can be found here. Insiders sold a total of 302,858 shares of company stock valued at $7,980,629 over the last 90 days. Insiders own 2.85% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in EXEL. Fisher Asset Management LLC increased its holdings in Exelixis by 232.6% in the fourth quarter. Fisher Asset Management LLC now owns 1,041 shares of the biotechnology company’s stock valued at $25,000 after buying an additional 728 shares in the last quarter. Rise Advisors LLC purchased a new stake in shares of Exelixis during the first quarter worth about $28,000. Park Place Capital Corp purchased a new stake in shares of Exelixis during the second quarter worth about $45,000. GAMMA Investing LLC increased its stake in shares of Exelixis by 107.9% during the second quarter. GAMMA Investing LLC now owns 2,006 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 1,041 shares in the last quarter. Finally, EntryPoint Capital LLC increased its stake in shares of Exelixis by 537.2% during the first quarter. EntryPoint Capital LLC now owns 2,071 shares of the biotechnology company’s stock worth $49,000 after purchasing an additional 1,746 shares in the last quarter. Hedge funds and other institutional investors own 85.27% of the company’s stock.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.